Urology
Volume 73, Issue 5, Supplement , Pages S11-S20 , May 2009

Critical Appraisal of Prostate-specific Antigen in Prostate Cancer Screening: 20 Years Later

  • Kenneth J. Pienta

      Affiliations

    • Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan, USA
    • Department of Urology, University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
    • Corresponding Author InformationReprint requests: Kenneth J. Pienta, M.D., Department of Internal Medicine, University of Michigan Comprehensive Cancer Center, 7308 CCC, 1500 East Medical Center Drive, Ann Arbor, MI 48109

Received 2 February 2009 ,Accepted 20 February 2009.

References 

  1. Loeb S, Catalona WJ. What to do with an abnormal PSA test. Oncologist. 2008;13:299–305
  2. Cooner WH, Mosley BR, Rutherford CL, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol. 1990;143:1146–1152
  3. Gann PH, Hennekens CH, Stampfer MJ. A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer. JAMA. 1995;25:289–294
  4. Ulmert D, Cronin AM, Bjork T, et al. Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: a case-control study. BMC Med. 2008;6:6–13
  5. Hara M, Inoue T, Koyanagi Y. Preparation and immunoelectrophoretic assessment of antisera to human seminal plasma. Nippon Hoigaku Zasshi. 1996;20:365
  6. Wang MC, Valenzuela LA, Murphy GP, et al. Purification of a human prostate specific antigen: 1979 [classical article]. J Urol. 2002;167:1226–1230
  7. Gutman AB, Gutman EB. An “acid” phosphatase occurring in the serum of patients with metastasizing carcinoma of the prostate gland. J Clin Invest. 1938;17:473–478
  8. Bensalah K, Lotan Y, Karam JA, et al. New circulating biomarkers for prostate cancer. Prostate Cancer Prostatic Dis. 2008;11:112–120
  9. Scardino PT. The Gordon Wilson lecture: natural history and treatment of early stage prostate cancer. Trans Am Clin Climatol Assoc. 2000;111:201–241
  10. Christensson A, Bjork T, Nilsson O, et al. Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J Urol. 1993;150:100–105
  11. Mikolajczyk SD, Millar LS, Wang TJ, et al. “BPSA,” a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology. 2000;55:41–45
  12. Mikolajczyk SD, Millar LS, Wang TJ, et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res. 2000;60:756–759
  13. Mikolajczyk SD, Catalona WJ, Evans CL, et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem. 2004;50:1017–1025
  14. Catalona WJ, Bartsch G, Rittenhouse HG, et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol. 2004;171(6 Pt. 1):2239–2244
  15. Lee F, Torp-Pedersen ST, Siders DB, et al. Transrectal ultrasound in the diagnosis and staging of prostatic carcinoma. Radiology. 1989;170(3 Pt. 1):609–615
  16. Mettlin C, Murphy GP, Lee F, et al. Investigators of the American Cancer Society-National Prostate Cancer Detection Project Characteristics of prostate cancers detected in a multimodality early detection program. Cancer. 1993;72:1701–1708
  17. Littrup PJ, Lee F, Mettlin C. Prostate cancer screening: current trends and future implications. CA Cancer J Clin. 1992;42:198–211
  18. Lowe FC, Trauzzi SJ. Prostatic acid phosphatase in 1993: its limited clinical utility. Urol Clin North Am. 1993;20:589–595
  19. Makarov DV, Carter HB. The discovery of prostate specific antigen as a biomarker for the early detection of adenocarcinoma of the prostate. J Urol. 2006;176(6 Pt. 1):2383–2385
  20. Romero FR, Romero KR, Brenny FT, et al. Reasons why patients reject digital rectal examination when screening for prostate cancer. Arch Esp Urol. 2008;61:759–765
  21. Thompson IM, Ankerst DP, Chi C, et al. Assessing prostate cancer risk: results from the Prostate Cancer Prevention Trial. J Natl Cancer Inst. 2006;98:529–534
  22. Borden LS, Wright JL, Kim J, et al. An abnormal digital rectal examination is an independent predictor of Gleason ≥7 prostate cancer in men undergoing initial prostate biopsy: a prospective study of 790 men. BJU Int. 2007;99:559–563
  23. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987;317:909–916
  24. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156–1161
  25. Hernandez DJ, Han M, Humphreys EB, et al. Predicting the outcome of prostate biopsy: comparison of a novel logistic regression-based model, the prostate cancer risk calculator, and prostate-specific antigen level alone. BJU Int. 2009;103:609–614
  26. Brawer MK, Beatie J, Wener MH, et al. Screening for prostatic carcinoma with prostate specific antigen: results of the second year. J Urol. 1993;150:106–109
  27. Brawer MK, Chetner MP, Beatie J, et al. Screening for prostatic carcinoma with prostate specific antigen. J Urol. 1992;147(3 Pt. 2):841–845
  28. Terris MK, Stamey TA. Utilization of polyclonal serum prostate specific antigen levels in screening for prostate cancer: a comparison with corresponding monoclonal values. Br J Urol. 1994;73:61–64
  29. Hernández J, Thompson IM. Prostate-specific antigen: a review of the validation of the most commonly used cancer biomarker. Cancer. 2004;101:894–904
  30. Henkel J. Prostate cancer: new tests create treatment dilemmas. FDA Consumer. December 1994;http://www.fda.gov/fdac/reprints/prostate.htmlUpdated 1997. Accessed December 16, 2008
  31. Welch HG, Schwartz LM, Woloshin S. Prostate-specific antigen levels in the United States: implications of various definitions for abnormal. J Natl Cancer Inst. 2005;97:1132–1137
  32. Thompson I, Thrasher JB, Aus G, et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007;177:2106–2131
  33. Bartsch G, Horninger W, Klocker H, et al. Tyrol Prostate Cancer Demonstration Project: early detection, treatment, outcome, incidence and mortality. BJU Int. 2008;101:809–816
  34. Carter HB, Morrell CH, Pearson JD, et al. Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostate disease. Cancer Res. 1992;52:3323–3328
  35. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer. 1993;72:2638–2643
  36. Carter HB, Pearson JD. PSA velocity for the diagnosis of early prostate cancer: a new concept. Urol Clin North Am. 1993;20:665–670
  37. Lilja H, Ulmert D, Vickers AJ. Prostate-specific antigen and prostate cancer: prediction, detection and monitoring. Nat Rev Cancer. 2008;8:268–278
  38. Oesterling JE, Jacobsen SJ, Chute CG, et al. Serum prostate-specific antigen in a community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860–864
  39. Morgan TO, Jacobsen SJ, McCarthy WF, et al. Age-specific reference ranges for prostate-specific antigen in black men. N Engl J Med. 1996;335:304–310
  40. Evans S, Metcalfe C, Ibrahim F, et al. Differences in prostate cancer prognosis: a systematic review and metal-analysis. Int J Cancer. 2008;123:430–435
  41. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6 to 4.0 ng/mL and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452–1455
  42. Punglia RS, D'Amico AV, Catalona WJ, et al. Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen. N Engl J Med. 2003;349:335–342
  43. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level ≤4.0 ng per milliliter. N Engl J Med. 2004;350:2239–2246
  44. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–541
  45. Guess HA, Heyse JF, Gormley GJ, et al. Effect of finasteride on serum PSA concentration in men with benign prostatic hyperplasia: results from the North American phase III clinical trial. Urol Clin North Am. 1993;20:627–636
  46. Thompson IM, Chi C, Ankerst DP, et al. Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. J Natl Cancer Inst. 2006;98:1128–1133
  47. Andriole G, Bostwick D, Brawley O, et al. Chemoprevention of prostate cancer in men at high risk: rationale and design of the reduction by dutasteride of prostate cancer events (REDUCE) trial. J Urol. 2004;172(4 Pt. 1):1314–1317
  48. Oesterling JE. Prostate-specific antigen and diagnosing early malignancies of the prostate. J Cell Biochem Suppl. 1992;16H:31–43
  49. el-Shirbiny AM. Prostatic specific antigen. Adv Clin Chem. 1994;31:99–133
  50. Heidenreich A, Aus G, Bolla M, et al. EAU guidelines on prostate cancer. Eur Urol. 2008;53:68–80
  51. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology: prostate cancer early detection. V.2 http://www.nccn.org2007;Updated May 10, 2007. Accessed December 24, 2008
  52. Carter HB, Ferrucci L, Kettermann A, et al. Detection of life-threatening prostate cancer with prostate-specific antigen velocity during a window of curability. J Natl Cancer Inst. 2006;98:1521–1527
  53. Ashley T. Using predictive value, sensitivity and specificity to interpret laboratory tests: PSA for the diagnosis of prostate cancer. J Insur Med. 2005;37:261–263
  54. Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am. 1997;24:293–297
  55. Erdogan K, Gurdal M, Tekin A, et al. The effect of urethral catheterisation on serum prostate-specific antigen levels in male patients with acute urinary retention. Yonsei Med J. 2003;44:676–678
  56. Parekh N, Lin Y, Marcella S, et al. Associations of lifestyle and physiologic factors with prostate-specific antigen concentrations: evidence from the National Health and Nutrition Examination Survey (2001-2004). Cancer Epidemiol Biomarkers Prev. 2008;17:2467–2472
  57. Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol. 2007;25:3–9
  58. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin. 2008;58:71–96
  59. Thompson IM, Ankerst DP. Prostate-specific antigen in the early detection of prostate cancer. Can Med Assoc J. 2007;176:1853–1858
  60. American Cancer Society. Cancer facts and figures 2008. http://www.cancer.org/docroot/stt/stt_0.aspAccessed December 9, 2008
  61. Tarone RE, Chu KC, Brawley OW. Implications of stage-specific survival rates in assessing recent declines in prostate cancer mortality rates. Epidemiology. 2000;11:167–170
  62. Bouchardy C, Fioretta G, Rapiti E, et al. Recent trends in prostate cancer mortality show a continuous decrease in several countries. Int J Cancer. 2008;123:421–429
  63. Clements A, Watson E, Rai T, et al. The PSA testing dilemma: GPs' reports of consultations with asymptomatic men: a qualitative study. BMC Fam Pract. 2007;8:35–41
  64. Ekwueme DU, Stroud LA, Chen Y. Cost analysis of screening for, diagnosing, and staging prostate cancer based on a systematic review of published studies. Prev Chronic Dis. 2007;4:A100–A116
  65. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials. 2000;21(suppl):273S–309S
  66. Zoorob R, Anderson R, Cefalu C, Sidani M. Cancer screening guidelines. Am Fam Physician. 2001;63:1101–1112
  67. Andriole GL, Levin DL, Crawford ED, et al. Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst. 2005;97:433–438
  68. Schröder FH. Screening for prostate cancer (PC)—an update on recent findings of the European Randomised Study of Screening for Prostate Cancer (ERSPC). Urol Oncol. 2008;26:533–541
  69. Roobol MJ, Roobol DW, Schröder FH. Is additional testing necessary in men with prostate-specific antigen levels of 1.0 ng/mL or less in a population-based screening setting? ((ERSPC, section Rotterdam)). Urology. 2005;65:343–346
  70. U.S. Preventive Services Task Force recommendation statement. Screening for prostate cancer. Ann Intern Med. 2008;149:185–191
  71. Lin K, Lipsitz R, Miller T, et al. Benefits and harms of prostate-specific antigen screening for prostate cancer: an evidence update for the U.S. Preventive Services Task Force. Ann Intern Med. 2008;149:192–199
  72. Davidov O, Zelen M. Overdiagnosis in early detection programs. Biostatistics. 2004;5:603–613
  73. Etzioni R, Penson DF, Legler JM, et al. Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. J Natl Cancer Inst. 2002;94:981–990
  74. Taichman RS, Loberg RD, Mehra R, et al. The evolving biology and treatment of prostate cancer. J Clin Invest. 2007;117:2351–2361
  75. Graif T, Loeb S, Roehl KA, et al. Under diagnosis and over diagnosis of prostate cancer. J Urol. 2007;178:88–92
  76. Pelzer AE, Bektic J, Akkad T, et al. Under diagnosis and over diagnosis of prostate cancer in a screening population with serum PSA 2 to 10 ng/ml. J Urol. 2007;178:93–97
  77. Penson DF, Schonfeld WH, Flanders SC, et al. Relationship of first-year costs of treating localized prostate cancer to initial choice of therapy and stage at diagnosis: results from the CaPSURE database. Urology. 2001;57:499–503
  78. Barry MJ, Fleming C, Coley CM, et al. Should Medicare provide reimbursement for prostate-specific antigen testing for early detection of prostate cancer? (Part IV: estimating the risks and benefits of an early detection program). Urology. 1995;46:445–461
  79. Coley CM, Barry MJ, Fleming C, et al. Early detection of prostate cancer (Part II: estimating the risks, benefits, and costs). Ann Intern Med. 1997;126:468–479
  80. Crawford ED, Abrahamsson PA. PSA-based screening for prostate cancer: how does it compare with other cancer screening tests?. Eur Urol. 2008;54:262–273
  81. Harris R, Lohr KN. Screening for prostate cancer: an update of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;137:917–929
  82. Andriole GL, Grubb RL, Buys SS, et al. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med. 2009;360:1310–1319
  83. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med. 2009;360:1320–1328

 K. J. Pienta, M.D., is a consultant to GlaxoSmithKline.

PII: S0090-4295(09)00237-4

doi: 10.1016/j.urology.2009.02.016

Urology
Volume 73, Issue 5, Supplement , Pages S11-S20 , May 2009

Article Tools

* Image Usage & Resolution